31 The overall TRIUMPH1 and TRIUMPH2 sample sizes provide at least 90% power to detect clinically meaningful weight reduction with retatrutide at 9 and 12 mg doses versus placebo on percent change in body weight, assuming each dose is analysed separately in parallel using a 2sample t test at a 2sided significance level of 0.0125
CrossRef Second-Line and Subsequent Therapies after Atezolizumab Plus Bevacizumab Treatment in Hepatocellular Carcinoma: A Multicenter Prospective Cohort Study Yuri Cho, Jeong-Hoon Lee, Baek-Yeol Ryoo, Ho Yeong Lim, Dong Eun Lee, Bo Hyun Kim, Joong-Won Park Gut and Liver .2026
Aggressive early escalation that compromises nutrition and produces dropout is not superior to gradual escalation that produces a completed 12-month course
Mechanisms of action and therapeutic application of GLP-1. Cell Metabolism , 2021.
Beyond weight, the glucagon receptor agonism component carries theoretical benefits for non-alcoholic fatty liver disease (NAFLD), now reclassified as metabolic dysfunction-associated steatotic liver disease (MASLD)
Side-effects like nausea and digestive disorders usually resolve themselves, and those like pancreatitis, thyroid cancer and blindness are very uncommon
